FDA
-
-
-
-
-
-
-
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
-
-
-
-
-
-
-
NextCure Inc. (NXTC) doses first patient in Phase 1 study of LNCB74
-
-
-
-
-
-
-
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
NextCure Inc. (NXTC) Appoints Ellen G. Feigal and Anne Borgman to its Board
-
-
-
-
-
-
-
Dr. Han Myint Appointed as NextCure’s Chief Medical Officer
-
-
-
-
-
-
-
NextCure Reports Fourth Quarter and Full Year 2019 Financial Results
-
-
-
-
-
-
322,140 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

